Source: Health Products Regulatory Authority (IE) Revision Year: 2019 Publisher: Laboratoire HRA Pharma, 200 avenue de Paris, 92320 CHATILLON, France
NORLEVO 1.5 mg tablet.
| Pharmaceutical Form |
|---|
|
Tablet. White, round biconvex tablet engraved with code NL 1.5 on one face. |
Each tablet contains 1.5 mg levonorgestrel.
Excipient with known effect: each tablet contains 90.90 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Levonorgestrel |
The precise mode of action of levonorgestrel as an emergency contraceptive is not known. At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase, when the likelihood of fertilisation is the highest. |
| List of Excipients |
|---|
|
Lactose monohydrate |
PVC/PE/PVDC/Aluminium blister of 1 tablet.
Pack sizes with 1 tablet and 5, 10, 25 or 50 tablets as hospital packs only.
Not all pack sizes may be marketed.
Laboratoire HRA Pharma, 200 avenue de Paris, 92320 CHATILLON, France
PA1166/002/001
Date of first authorisation: 26th August 2005
Date of last renewal: 19th April 2009
| Drug | Countries | |
|---|---|---|
| NORLEVO | Cyprus, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Netherlands, Tunisia, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
